Redeye makes negligible estimate revisions on the back of I-Tech’s strong Q3 figures, posting organic growth of 48% while growing EBIT by 69%. The regulatory process continues to color the share price sentiment, even though I-Tech has performed financially. The financial outlook remains promising with two potential product launches in the next 6-12 months.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

I-Tech – Q3 Report Shows Promising Outlook

© Modular Finance, source Nordic Press Releases